hydroxyurea has been researched along with Viremia in 17 studies
Viremia: The presence of viruses in the blood.
Excerpt | Relevance | Reference |
---|---|---|
"The goal of this study was to optimize the hydroxyurea dosage in HIV-infected patients, and to minimize the toxicity and maximize the antiviral efficacy of the hydroxyurea-didanosine combination." | 9.11 | Lowering the dose of hydroxyurea minimizes toxicity and maximizes anti-HIV potency. ( Asmuth, D; Bakare, N; Blick, G; Farthing, C; Foli, A; Frank, I; Greiger, P; Groff, A; Herman, D; Lisziewicz, J; Lori, F; Lova, L; Norris, D; Peterson, D; Pollard, RB; Rashbaum, B; Schrader, S; Shalit, P; Tennenberg, A; Whitman, L, 2005) |
"The goal of this study was to optimize the hydroxyurea dosage in HIV-infected patients, and to minimize the toxicity and maximize the antiviral efficacy of the hydroxyurea-didanosine combination." | 5.11 | Lowering the dose of hydroxyurea minimizes toxicity and maximizes anti-HIV potency. ( Asmuth, D; Bakare, N; Blick, G; Farthing, C; Foli, A; Frank, I; Greiger, P; Groff, A; Herman, D; Lisziewicz, J; Lori, F; Lova, L; Norris, D; Peterson, D; Pollard, RB; Rashbaum, B; Schrader, S; Shalit, P; Tennenberg, A; Whitman, L, 2005) |
" Overall, in 12 patients treated with hydroxyurea, 33 adverse events were reported versus 19 reported for 12 patients who did not receive hydroxyurea (p <." | 2.70 | Higher rate of toxicity with no increased efficacy when hydroxyurea is added to a regimen of stavudine plus didanosine and nevirapine in primary HIV infection. ( Cahn, P; Federico, A; Kijak, G; Montaner, JS; Ochoa, C; Perez, H; Salomon, H; Zala, C, 2002) |
"Hydroxyurea was found to induce lymphopenia (-124 x 10(6)/l)." | 2.69 | A placebo-controlled trial of didanosine plus stavudine, with and without hydroxyurea, for HIV infection. The Swiss HIV Cohort Study. ( Bernasconi, E; Bucher, HC; Hirschel, B; Iten, A; Leduc, D; Malinverni, R; Opravil, M; Perrin, LH; Rutschmann, OT; Sudre, P; Vernazza, PL; Yerly, S, 1998) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 7 (41.18) | 18.2507 |
2000's | 10 (58.82) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Lafeuillade, A | 2 |
Poggi, C | 2 |
Hittinger, G | 1 |
Counillon, E | 1 |
Emilie, D | 1 |
Foli, A | 4 |
Maserati, R | 2 |
Barasolo, G | 1 |
Castelli, F | 1 |
Tomasoni, L | 1 |
Migliorino, M | 1 |
Maggiolo, F | 1 |
Pan, A | 1 |
Paolucci, S | 1 |
Scudeller, L | 1 |
Tinelli, C | 3 |
D'Aquila, R | 1 |
Lisziewicz, J | 6 |
Lori, F | 6 |
Pollard, RB | 2 |
Whitman, L | 1 |
Bakare, N | 1 |
Blick, G | 1 |
Shalit, P | 1 |
Peterson, D | 1 |
Tennenberg, A | 1 |
Schrader, S | 1 |
Rashbaum, B | 1 |
Farthing, C | 1 |
Herman, D | 1 |
Norris, D | 1 |
Greiger, P | 1 |
Frank, I | 1 |
Groff, A | 1 |
Lova, L | 1 |
Asmuth, D | 1 |
Nunnari, G | 1 |
Leto, D | 1 |
Sullivan, J | 1 |
Xu, Y | 1 |
Mehlman, KE | 1 |
Kulkosky, J | 1 |
Pomerantz, RJ | 1 |
Lewin, SR | 1 |
Murray, JM | 1 |
Solomon, A | 1 |
Wightman, F | 1 |
Cameron, PU | 1 |
Purcell, DJ | 1 |
Zaunders, JJ | 1 |
Grey, P | 1 |
Bloch, M | 1 |
Smith, D | 1 |
Cooper, DA | 1 |
Kelleher, AD | 1 |
Pellegrino, P | 1 |
Profizi, N | 1 |
Thiebaut, C | 1 |
Simonelli, C | 1 |
Comar, M | 1 |
Zanussi, S | 1 |
De Paoli, P | 1 |
Tirelli, U | 1 |
Giacca, M | 1 |
De Antoni, A | 2 |
Malykh, AG | 1 |
Minoli, L | 1 |
Padrini, D | 1 |
Degli Antoni, A | 1 |
Barchi, E | 1 |
Jessen, H | 2 |
Wainberg, MA | 1 |
Gallo, RC | 1 |
Nokta, M | 1 |
Rossero, R | 1 |
Loesch, K | 1 |
Rutschmann, OT | 1 |
Opravil, M | 1 |
Iten, A | 1 |
Malinverni, R | 1 |
Vernazza, PL | 1 |
Bucher, HC | 1 |
Bernasconi, E | 1 |
Sudre, P | 1 |
Leduc, D | 1 |
Yerly, S | 1 |
Perrin, LH | 1 |
Hirschel, B | 1 |
Lieberman, J | 1 |
Clerici, M | 1 |
Barreiro, P | 1 |
de Mendoza, C | 1 |
Soriano, V | 1 |
González-Lahoz, J | 1 |
Lewis, MG | 1 |
Xu, J | 1 |
Varga, G | 1 |
Zinn, DE | 1 |
Crabbs, C | 1 |
Wagner, W | 1 |
Greenhouse, J | 1 |
Silvera, P | 1 |
Yalley-Ogunro, J | 1 |
Stranford, SA | 1 |
Ong, JC | 1 |
Martinez-Marino, B | 1 |
Busch, M | 1 |
Hecht, FM | 1 |
Kahn, J | 1 |
Levy, JA | 1 |
Reed, W | 1 |
Vichinsky, EP | 1 |
Zala, C | 1 |
Salomon, H | 1 |
Ochoa, C | 1 |
Kijak, G | 1 |
Federico, A | 1 |
Perez, H | 1 |
Montaner, JS | 1 |
Cahn, P | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
An Exploratory, Open-Label, Randomized Trial to Evaluate the Ability of Interleukin-2 (IL-2) to Enhance HIV-Specific Immunity and Influence the Time to Virologic Relapse Following Withdrawal of Potent Antiretroviral Therapy[NCT00038259] | 21 participants | Interventional | Completed | ||||
Antiretroviral-Sparing Concept: An Exploratory Phase II, Randomized, Single Blind Placebo-Controlled Study to Investigate the Effect of Therapeutic Immunization on the Quantity of HIV-Specific T Cell Precursors During Highly Active Antiretroviral Therapy [NCT00918840] | 16 participants (Actual) | Observational | 2009-04-30 | Completed | |||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
1 review available for hydroxyurea and Viremia
Article | Year |
---|---|
Transfusion therapy: a coming-of-age treatment for patients with sickle cell disease.
Topics: Adolescent; Adult; Aged; Anemia, Sickle Cell; Bacteremia; Blood Group Antigens; Blood Substitutes; B | 2001 |
11 trials available for hydroxyurea and Viremia
Article | Year |
---|---|
Predictors of plasma human immunodeficiency virus type 1 RNA control after discontinuation of highly active antiretroviral therapy initiated at acute infection combined with structured treatment interruptions and immune-based therapies.
Topics: Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; DNA, Viral; Drug Administration | 2003 |
Strategies to decrease viral load rebound, and prevent loss of CD4 and onset of resistance during structured treatment interruptions.
Topics: Anti-HIV Agents; CD4-Positive T-Lymphocytes; Didanosine; Drug Administration Schedule; Drug Resistan | 2004 |
Lowering the dose of hydroxyurea minimizes toxicity and maximizes anti-HIV potency.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; CD4-CD8 Ratio; Didanosine; Drug Therapy, Combination; Drug-Re | 2005 |
Seminal reservoirs during an HIV type 1 eradication trial.
Topics: Amino Acid Sequence; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Didanosine; DNA, Viral; | 2005 |
Virologic determinants of success after structured treatment interruptions of antiretrovirals in acute HIV-1 infection.
Topics: Adult; Anti-HIV Agents; DNA, Viral; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Hydrox | 2008 |
No therapeutic advantage from didanosine (ddI) and hydroxyurea versus ddI alone in patients with HIV infection.
Topics: CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Hydroxyurea; RN | 1997 |
Mutations in the pol gene of human immunodeficiency virus type 1 in infected patients receiving didanosine and hydroxyurea combination therapy.
Topics: Anti-HIV Agents; Didanosine; DNA, Complementary; Drug Resistance, Microbial; Drug Therapy, Combinati | 1997 |
Combination of a drug targeting the cell with a drug targeting the virus controls human immunodeficiency virus type 1 resistance.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; CD4 Lymphocyte Count; Cells; Didanosine; Dose-R | 1997 |
A placebo-controlled trial of didanosine plus stavudine, with and without hydroxyurea, for HIV infection. The Swiss HIV Cohort Study.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cohort Studies; Didanosine; Double-Blind Method; Drug | 1998 |
Immune restoration by combination of a cytostatic drug (hydroxyurea) and anti-HIV drugs (didanosine and indinavir).
Topics: Anti-HIV Agents; CD3 Complex; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymph | 1999 |
Higher rate of toxicity with no increased efficacy when hydroxyurea is added to a regimen of stavudine plus didanosine and nevirapine in primary HIV infection.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; Female; HIV Inf | 2002 |
5 other studies available for hydroxyurea and Viremia
Article | Year |
---|---|
Hydroxyurea and HIV-1 viraemia.
Topics: Acquired Immunodeficiency Syndrome; Didanosine; Drug Therapy, Combination; Enzyme Inhibitors; HIV In | 1995 |
Kinetics of tumor necrosis factor alpha and soluble TNFRII in HIV-infected patients treated with a triple combination of stavudine, didanosine, and hydroxyurea.
Topics: Adult; Anti-HIV Agents; Antigens, CD; CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; F | 1997 |
Hydroxyurea plus didanosine as maintenance therapy after 1 year on highly active antiretroviral therapy.
Topics: Anti-HIV Agents; Didanosine; Drug Therapy, Combination; Enzyme Inhibitors; HIV Infections; Humans; H | 2000 |
Control of SIV rebound through structured treatment interruptions during early infection.
Topics: Adenine; Animals; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; CD8- | 2000 |
Reduction in CD8+ cell noncytotoxic anti-HIV activity in individuals receiving highly active antiretroviral therapy during primary infection.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4-CD8 Ratio; CD4-Positive T-Lymphoc | 2001 |